For the quarter ended September 30, 2024, the Company had a loss from operations of $2.3 million, a 26% year-over-year improvement from $3.1 million for the comparable period of 2023, and a 9% ...

Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved more than 80% enrollmentPositive Type C ...

Instead of sending tourists to space, scientists have found a more practical use for the final frontier: growing better ...

Researchers led by Osaka University in Japan have conducted the first human trial using induced pluripotent stem-cell-derived ...

Aegle Therapeutics says that its mission is to harness the regenerative, immunomodulatory, and anti-inflammatory potential of ...

marks a significant advancement in stem cell therapy and offers hope for a potential cure for type 1 diabetes. While ...

In this webinar, Alex Rimmer, Samuel East, and Catriona Jamieson will discuss how they developed low-cost, animal-free ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Clinicians will soon gain access to trusted education on stem cell-based therapies through a new Continuing Education (CE) course developed by the International Society of Stem Cell Research (ISSCR).

Researchers found that neural crest stem cells are uniquely capable of reprogramming, challenging current reprogramming ...

My daughter's diagnosis of a rare and aggressive brain tumor at 3 years old made me strongly consider whether or not to have her treated with radiation.